Yahoo Finance

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society ...
Yahoo Finance

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 ...
Nasdaq

Corbus Pharmaceuticals Initiates PD-1 Combination Cohort in Phase 1 Study of CRB-701 for Solid Tumors

Corbus Pharmaceuticals initiates combination cohort of CRB-701 study for solid tumors, focusing on HNSCC and cervical cancer. Data update expected this year. Corbus Pharmaceuticals Holdings, Inc.
ascopubs.org

Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid ...

A phase I first-in-human clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in therapy-resistant non-muscle-invasive bladder cancer (NMIBC). This is an ASCO Meeting Abstract from the ...
KHON2

This new interim rule hopes to stop CRB movement throughout the state

HONOLULU (KHON2) — Hawaii continues its battle with coconut rhinoceros beetles moving from infested to non-infested areas throughout the state. Download the free KHON2 app for iOS or Android to stay ...
Business Insider

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- ...